<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathophysiology of von Willebrand disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathophysiology of von Willebrand disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathophysiology of von Willebrand disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paula James, MD, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         von Willebrand disease (VWD) is characterized by quantitative or qualitative abnormalities of von Willebrand factor (VWF), a crucial protein in hemostasis. Heritable VWD can be caused by pathogenic variants in the
         <em>
          VWF
         </em>
         gene, which lead to an impairment in the synthesis, secretion, clearance, or function of VWF. Acquired von Willebrand syndrome (AVWS) can be caused by several conditions that affect VWF levels and activity.
        </p>
        <p>
         The pathophysiology of VWD and AVWS will be reviewed here.
        </p>
        <p>
         Separate topic reviews discuss:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis of VWD
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of VWD
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">
          "von Willebrand disease (VWD): Treatment of major bleeding and major surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and treatment of AVWS
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/110531.html" rel="external">
          "Acquired von Willebrand syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H988979480">
         <span class="h1">
          INITIAL DESCRIPTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 1926, Erik von Willebrand described the first patient with the disease that now bears his name. The patient and her family members, many of whom were also affected, lived on the Åland Islands in the Gulf of Bothnia (in the Baltic Sea, between Finland and Sweden).
        </p>
        <p>
         The proband was severely affected and had multiple episodes of mucosal bleeding that led to her death at the age of 13 years. Four of her 11 siblings were also severely affected; 66 family members were studied. Von Willebrand named the disorder "hereditary pseudohemophilia" because he recognized the autosomal inheritance pattern, which contrasted with the X-linked inheritance pattern seen in hemophilia A and B [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         After an assay for factor VIII became available in the 1950s, patients with VWD were found to have decreased levels of factor VIII [
         <a href="#rid2">
          2
         </a>
         ]. Their bleeding could be treated with transfusion of plasma or partially purified preparations of factor VIII; these preparations are now known to contain VWF, which binds factor VIII in the circulation [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Stabilization of factor VIII'
         </a>
         below.)
        </p>
        <p>
         Considerable debate remained about the nature of the deficient factor in individuals with VWD, and there was uncertainty as to whether one or two proteins were involved. These questions were answered when the genes for factor VIII and VWF were cloned in the 1980s [
         <a href="#rid4">
          4-8
         </a>
         ]. (See
         <a class="local">
          'VWF gene'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1523203753">
         <span class="h1">
          VWF GENE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          VWF
         </em>
         gene is located on the short arm of chromosome 12; it is 178 kilobases (kb) in length and contains 52 exons [
         <a href="#rid6">
          6-9
         </a>
         ]; the VWF messenger ribonucleic acid (mRNA) is approximately 9 kb. A pseudogene on chromosome 22 includes exons 23-34 of the
         <em>
          VWF
         </em>
         gene that correspond to regions of the authentic gene encoding domains A1, A2, and A3 (see
         <a class="local">
          'Domain structure'
         </a>
         below) [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1994677182">
         <span class="h2">
          Genotype-phenotype correlations and inheritance patterns
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inherited VWD has been classified into three types  (
         <a class="graphic graphic_table graphicRef71525" href="/z/d/graphic/71525.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid12">
          12-14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type 1 is the most common, accounting for approximately 75 percent of patients. It represents a partial quantitative deficiency of VWF. Type 1 VWD is a complex genetic trait with contributions from many genes, including
         <em>
          VWF
         </em>
         , genes that regulate VWF synthesis and clearance, and genes that affect ABO blood group. (See
         <a class="medical medical_review" href="/z/d/html/14600.html" rel="external">
          "Principles of complex trait genetics"
         </a>
         and
         <a class="local">
          'Synthesis and multimerization'
         </a>
         below and
         <a class="local">
          'Clearance and control of plasma VWF levels'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Type 1 VWD is generally caused by heterozygosity for a variant that decreases VWF production, although in some individuals a causative variant cannot be found. It shows an autosomal dominant transmission pattern with incomplete penetrance and variable expressivity. Type 1C (increased VWF clearance) was added to the 2021 International Society of Thrombosis and Hemostasis (ISTH) classification of VWD [
         <a href="#rid15">
          15-17
         </a>
         ]. (See
         <a class="local">
          'Type 1 (reduced VWF)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type 2 is characterized by qualitative abnormalities of VWF. Four subtypes have been identified: 2A, 2B, 2M, and 2N. Type 2 is generally caused by heterozygosity for a variant that alters VWF function. The transmission pattern is usually an autosomal dominant, although type 2N and some individuals with other subtypes show autosomal recessive transmission. (See
         <a class="local">
          'Type 2 (dysfunctional protein; 2A, 2B, 2M, 2N)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type 3 is very rare, characterized by total deficiency of VWF with severe bleeding manifestations. This is generally caused by homozygosity or compound heterozygosity for variants that abolish VWF production. The transmission pattern is autosomal recessive. (See
         <a class="local">
          'Type 3 (undetectable VWF)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Clinical features and laboratory findings that distinguish the types of VWD are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease", section on 'Summary of VWD types'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease", section on 'Additional testing to characterize (classify) the type of VWD'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H76034300">
         <span class="h2">
          Spectrum of pathogenic variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          VWF
         </em>
         gene is highly polymorphic, and numerous polymorphisms (benign variants) contribute to the large variation in normal VWF levels [
         <a href="#rid18">
          18,19
         </a>
         ]. Polymorphisms in non-
         <em>
          VWF
         </em>
         genes also contribute to the variation in VWF levels; ABO blood group determinants, which affect the rate of VWF clearance, account for approximately 25 percent of the variance in VWF levels [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="local">
          'Clearance and control of plasma VWF levels'
         </a>
         below.)
        </p>
        <p>
         Pathogenic variants in the
         <em>
          VWD
         </em>
         gene are genetic changes (point mutations, deletions, insertions) that either decrease VWF levels below the normal range or result in a dysfunctional protein with activity below the normal range [
         <a href="#rid21">
          21,22
         </a>
         ]. Compilations of
         <em>
          VWF
         </em>
         variants can be found on the Leiden Open Variation Database (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdatabases.lovd.nl%2Fshared%2Fvariants%2FVWF%2Funique&amp;token=hwlBMygTvebQR3qzrrjEJ7Gw18NruPiosuiiYFCT0SYU8z11wNpLkR0B%2FD6gBBtITcr9X3Bl6pRFEteRI8xGpw%3D%3D&amp;TOPIC_ID=1309" target="_blank">
          LOVD
         </a>
         ) or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F%3Fterm%3DVWF%255bgene%255d&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trydXpHrlRjlT88GyxPjFjUkN36gYLl74bpR8Ex5bxlDTq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=1309" target="_blank">
          ClinVar
         </a>
         .
        </p>
        <p>
         A compilation of
         <em>
          VWF
         </em>
         variants with explanatory notes on &gt;750 unique variants was published in 2017 [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2303953676">
         <span class="h3">
          Type 1 (reduced VWF)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Type 1 VWD is characterized by partial deficiency of VWF (VWF antigen and/or activity &lt;30 percent, or 30 to 50 percent with a positive bleeding history). (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Hundreds of pathogenic variants in the
         <em>
          VWF
         </em>
         gene, mostly missense mutations, have been described in individuals with type 1 VWD [
         <a href="#rid22">
          22-31
         </a>
         ]. Variants affecting introns have also been described [
         <a href="#rid31">
          31-33
         </a>
         ]. It is likely that additional variants remain unidentified.
        </p>
        <p>
         These variants can reduce VWF levels in several ways [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decreased production
         </strong>
         – VWF production can be decreased by a null allele, which can result from a nonsense mutation, frameshift mutation, small deletion or insertion, or splice site mutation. A deletion in the
         <em>
          VWF
         </em>
         promoter that alters the binding of transcription factors has also been identified [
         <a href="#rid28">
          28
         </a>
         ]. Variants causing mRNA degradation have been described in several patients [
         <a href="#rid34">
          34
         </a>
         ]. A variant with deletion of exons 4 and 5 causes reduced expression from the unaffected allele [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Synthesis and multimerization'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decreased secretion
         </strong>
         – Some variants interfere with intracellular transport of VWF and/or cause VWF to be retained in different cellular compartments including endoplasmic reticulum, Golgi, or Weibel-Palade bodies [
         <a href="#rid27">
          27,36-39
         </a>
         ]. Some of these variants affect cysteine residues and may modify disulfide bond formation, causing inhibition of VWF multimer assembly and retention of abnormal VWF intracellularly. One study identified the Y1584C variant (substitution of cysteine for tyrosine at amino acid 1584), which leads to intracellular VWF retention, in 10 of 70 (14 percent) Canadian kindreds with type 1 VWD, suggesting a founder effect [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased clearance (type 1C)
         </strong>
         – VWF levels will be lower if clearance from the circulation is increased. Variants that increase VWF clearance often affect D3 domain (see
         <a class="local">
          'Domain structure'
         </a>
         below), although variants are dispersed throughout the gene, with higher frequencies at the amino-termini and carboxyl-termini [
         <a href="#rid21">
          21,40
         </a>
         ]. An example is the Vicenza mutation, the most commonly seen variant that leads to increased clearance [
         <a href="#rid41">
          41
         </a>
         ]. Some investigators refer to type 1 VWD that occurs by this mechanism as type 1C VWD. The Vicenza variant, which has larger-than-normal multimers and an abnormal multimer banding pattern, is a type 1C variant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An assay for variants that increase clearance uses detection the VWF propeptide (VWFpp) and that is cleaved and released in equimolar concentration with mature VWF, and determination of the ratio of VWFpp to the mature VWF protein (VWFpp:VWF:Ag ratio) [
         <a href="#rid15">
          15,16,29,40-45
         </a>
         ]. Variants with increased clearance show an increased VWFpp:VWF:Ag ratio, as clearance of VWFpp is unaffected while the clearance of VWF:Ag (the mature protein) is increased. A ratio &gt;3 has been used to designate "rapid clearance" of VWF [
         <a href="#rid40">
          40
         </a>
         ]. However, information about VWD half-life can also be obtained from a DDAVP trial, which is preferred for clinical management because it also provides information about the therapeutic effect of DDAVP. (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease", section on 'Specialized tests for VWD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP trial'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The clinical presentation of type 1 VWD varies from mild to severe as determined by bleeding symptoms. Some individuals with type 1 disease are asymptomatic and have been discovered in studies investigating a relative with type 3 disease. In addition to only one functioning allele, the presence or absence of bleeding within type 1 kindreds may be due to interactions with variants in other genes that reduce VWF expression or activity or that affect functions of other hemostatic proteins such as specific platelet collagen adhesion receptors [
         <a href="#rid46">
          46,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6683.html" rel="external">
          "Platelet biology and mechanism of anti-platelet drugs", section on 'Collagen receptors (GPIa/IIa and GPVI)'
         </a>
         .)
        </p>
        <p>
         Most type 1 VWD is autosomal dominant. This is the most common type of VWD, accounting for approximately 75 percent of cases.
        </p>
        <p class="headingAnchor" id="H392634780">
         <span class="h3">
          Type 2 (dysfunctional protein; 2A, 2B, 2M, 2N)
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several subtypes of Type 2 VWD that differ in which aspect of VWF function is affected. Because the protein abundance can be normal, these dysfunctional variants are characterized by a discrepancy between protein level (VWF:Ag) and platelet-dependent VWF activity, such as ristocetin cofactor activity (VWF:RCo, often used in the United States) or binding to mutant GPIb (VWF:GPIbM, used in many countries). The ratio of VWF:RCo to VWF:Ag can be used to identify type 2; a ratio of &lt;0.7 is often seen. (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease", section on 'Derived ratios to aid classification'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2A (reduced large multimers)
         </strong>
         – Type 2A is characterized by a reduction in high molecular weight VWF multimers, due to reduced dimerization or multimerization. This is caused by many types of variants including missense mutations, deletions, insertions, and frameshift mutations; approximately 90 percent are missense mutations [
         <a href="#rid48">
          48
         </a>
         ]. Many affect cysteine residues, indicating the importance of disulfide bonds in VWF multimerization. Many are located in the CK, D2, or D3 regions; D2 is in the propeptide region that is cleaved off to produce the mature monomer  (
         <a class="graphic graphic_figure graphicRef60152" href="/z/d/graphic/60152.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid49">
          49-58
         </a>
         ]. Some type 2A variants cause intracellular retention, defective biosynthesis, or abnormal storage of VWF; these are referred to as type 2A group I [
         <a href="#rid48">
          48,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some type 2A variants are located in the A2 region, where the ADAMTS13 cleavage site is located; these act by increasing susceptibility of VWF to proteolysis by ADAMTS13 (referred to as type 2, group II variants) [
         <a href="#rid48">
          48,59,60
         </a>
         ]. Other variants may affect several mechanisms of multimer formation [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'Multimer cleavage by ADAMTS13'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some variants in the propeptide (VWF:pp) that alter multimer formation (previously called type 2C VWD) and the A2801D variant (substitution of aspartic acid for alanine at amino acid 2801), which prevents dimer formation (previously called type 2D VWD), act in a dominant fashion [
         <a href="#rid62">
          62-65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with type 2A VWD generally present with moderate to moderately severe bleeding. Multimer analysis will show characteristic loss of large multimers. (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease", section on 'VWF multimer analysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Type 2A is usually transmitted as an autosomal dominant trait. However, recessive forms of type 2A also exist. Type 2A VWD accounts for approximately 10 to 20 percent of cases of VWD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2B (increased binding to platelets)
         </strong>
         – Type 2B (type 2B) is characterized by loss of high molecular weight multimers and
         <strong>
          increased
         </strong>
         binding of VWF to platelets via the platelet receptor glycoprotein Ib (GPIb) [
         <a href="#rid60">
          60,66,67
         </a>
         ]. These variants often affect the A1 domain (a 38 amino acid sequence on opposite side of the A1 domain as type 2M variants) or, infrequently, the D3 domain  (
         <a class="graphic graphic_figure graphicRef60152" href="/z/d/graphic/60152.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid40">
          40,60,68,69
         </a>
         ]. The A1 domain variants alter the binding site of VWF to platelet GPIb alpha to increase binding, which causes VWF and bound platelets to be sequestered from the circulation, possibly due to clearance of small platelet aggregates [
         <a href="#rid70">
          70-72
         </a>
         ]. They are almost always (&gt;95 percent) due to missense mutations [
         <a href="#rid48">
          48
         </a>
         ]. Type 2B contrasts with type 2M, which is characterized by reduced binding of VWF to platelet GPIb.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Montreal platelet syndrome
         </strong>
         – Patients previously diagnosed as having the Montreal platelet syndrome, characterized by moderately severe thrombocytopenia, mucocutaneous bleeding, giant platelets, and spontaneous in vitro platelet aggregation, have been shown to have type 2B VWD due to the
         <em>
          VWF
         </em>
         V1316M mutation in exon 28 [
         <a href="#rid73">
          73,74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type 2B New York/Malmö
         </strong>
         – This variant is characterized by a normal pattern of high molecular weight multimers at baseline, with loss of high molecular weight multimers and development of thrombocytopenia under stress situations that lead to increased release of the mutant VWF (eg, after DDAVP) [
         <a href="#rid75">
          75
         </a>
         ]. This is due to mutations affecting the D3 domain [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with type 2B VWD generally present with moderately severe bleeding and usually show decreased high molecular weight multimers, a low ratio of VWF:RCo to VWF:Ag, increased ristocetin-induced platelet aggregation, and thrombocytopenia. Thrombocytopenia may be an independent risk factor for bleeding [
         <a href="#rid72">
          72,73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is some variation in expert opinion regarding whether individuals with type 2B should have a trial of DDAVP, due to the possible risk of exacerbating thrombocytopenia. (See
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP trial'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Type 2B is transmitted in an autosomal dominant pattern. It accounts for approximately 5 percent of cases of VWD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Phenotypic abnormalities similar to VWD type 2B can also be produced by variants in the gene that encodes the GPIb receptor that cause it to bind more avidly to normal VWF; this disorder is called platelet-type or pseudo VWD [
         <a href="#rid76">
          76,77
         </a>
         ]. This is a platelet disease, not an aberration in VWF. (See
         <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">
          "Inherited platelet function disorders (IPFDs)", section on 'Specific disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2M (decreased binding to platelets)
         </strong>
         – Type 2M VWD is characterized by normal multimers and
         <strong>
          reduced
         </strong>
         binding of VWF to platelet GPIb, or, less commonly, decreased binding of VWF to collagen [
         <a href="#rid78">
          78
         </a>
         ]. Type 2M variants cause decreased platelet adhesion to sites of injury [
         <a href="#rid60">
          60,78
         </a>
         ]. (See
         <a class="local">
          'Bridging between platelets and vascular subendothelium'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most type 2M variants are located in the A1 domain (the opposite end of the domain from those that cause type 2B VWD) [
         <a href="#rid60">
          60
         </a>
         ]. Some individuals with decreased binding to collagen are also classified as having type 2M VWD; these variants are located in the A1 and A3 domains [
         <a href="#rid23">
          23,79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with type 2M typically have significant bleeding symptoms [
         <a href="#rid78">
          78,80,81
         </a>
         ]. Bleeding symptoms are related to decreased interactions of platelets with the vascular endothelium. (See
         <a class="local">
          'Bridging between platelets and vascular subendothelium'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Type 2M is transmitted in an autosomal dominant pattern. It is less common than types 2A or 2B.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2N (decreased binding to factor VIII)
         </strong>
         – Type 2N VWD (N stands for Normandy, where one of the first patients was described) is characterized by decreased binding of VWF to factor VIII.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most type 2N variants are distributed throughout a 91 amino acid region of the amino-terminus of the mature VWF monomer including the D' and D3 domains  (
         <a class="graphic graphic_figure graphicRef60152" href="/z/d/graphic/60152.html" rel="external">
          figure 1
         </a>
         ), which include the factor VIII binding site [
         <a href="#rid59">
          59,82-88
         </a>
         ]. Binding of VWF to factor VIII protects circulating factor VIII from proteolysis; Some patients with type 2N also have impaired VWF multimerization [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with type 2N have low factor VIII (usually 5 to 15 percent of normal); their bleeding phenotype is at least partly due to factor VIII deficiency, resulting in joint and soft tissue bleeding. There can be normal VWF antigen (VWF:Ag) and ristocetin cofactor activity (VWF:RCo) and deficient factor VIII; some individuals are misdiagnosed as having hemophilia A. However, in type 2N the transmission pattern is autosomal recessive, with females affected at the same frequency and to the same degree as males, whereas hemophilia A is X-linked [
         <a href="#rid85">
          85,86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">
          "Clinical manifestations and diagnosis of hemophilia", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Type 2N inheritance is autosomal recessive trait; homozygosity is generally required for type 2N to manifest. In a heterozygous carrier for a type 2N variant, the unaffected allele usually produces enough functional VWF to bind and stabilize factor VIII and prevent factor VIII deficiency. Type 2N may also be caused by compound heterozygosity for a type 2N variant and a pathogenic variant in the
         <em>
          F8
         </em>
         gene (hemophilia A carrier) or compound heterozygosity for a type 2N variant and a
         <em>
          VWF
         </em>
         variant that decreases VWF levels enough to eliminate the factor VIII stabilizing function [
         <a href="#rid86">
          86,90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3820134807">
         <span class="h3">
          Type 3 (undetectable VWF)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Type 3 VWD is characterized by a marked decrease or absence of detectable VWF [
         <a href="#rid12">
          12-14
         </a>
         ]. This is caused by homozygosity or compound heterozygosity for variants that substantively reduce or abolish VWF production. These variants include nonsense, missense, and splice site mutations and often partial or complete deletions (most common). Nondeletional variants can result in the loss of VWF mRNA expression or impaired secretion and intracellular retention [
         <a href="#rid21">
          21,91-95
         </a>
         ].
        </p>
        <p>
         Individuals with compound heterozygous variants often have a VWF protein that is not secreted or undergoes rapid clearance [
         <a href="#rid96">
          96
         </a>
         ]. A common variant involves a frameshift mutation in exon 18; this was demonstrated to be the variant present in the initial kindred described by von Willebrand [
         <a href="#rid97">
          97,98
         </a>
         ]. (See
         <a class="local">
          'Initial description'
         </a>
         above.)
        </p>
        <p>
         Type 3 patients have severe bleeding due to decreased or absent VWF-related platelet function (mucocutaneous bleeding) as well as significantly decreased factor VIII function (joint and soft tissue bleeding) (see
         <a class="local">
          'Stabilization of factor VIII'
         </a>
         below). Affected individuals may be initially misdiagnosed as having hemophilia A. (See
         <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">
          "Clinical manifestations and diagnosis of hemophilia", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         Type 3 VWD is transmitted in an autosomal recessive pattern. Children of an individual with type 3 VWD who only inherit one of the variants may have type 1 disease. Type 3 VWD is rare (estimated prevalence 1 in 1 million) [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2336337390">
         <span class="h1">
          VWF PROTEIN
         </span>
        </p>
        <p class="headingAnchor" id="H502097798">
         <span class="h2">
          Domain structure
         </span>
         <span class="headingEndMark">
          —
         </span>
         VWF is a large multimeric glycoprotein [
         <a href="#rid100">
          100
         </a>
         ]. It is composed of a series of homologous domains, with most regions repeated three to six times. These include (in order) three D domains, three A domains, a fourth D domain, and six C domains [
         <a href="#rid101">
          101
         </a>
         ]. The carboxyl terminus of the protein contains a carboxyl-terminal cysteine knot (CTCK) [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         Each domain has different functional properties  (
         <a class="graphic graphic_figure graphicRef60152" href="/z/d/graphic/60152.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         D' and the contiguous part of D3 contains the binding site for factor VIII [
         <a href="#rid103">
          103-105
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A1 contains binding sites for platelet GPIb, heparin, collagen, and ristocetin [
         <a href="#rid60">
          60,66,106
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A2 contains the cleavage site for ADAMTS13 [
         <a href="#rid60">
          60,107
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A3 contains the primary binding site for collagen [
         <a href="#rid60">
          60
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         C4 contains a binding site for the platelet integrin alphaIIb-beta3 (GPIIbIIIa) [
         <a href="#rid102">
          102
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CTCK contains the dimerization interface [
         <a href="#rid102">
          102
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Each D domain (referred to as a "D assembly") is subdivided into several modules based on their electron microscopic appearance; they are named VWD C8 (cysteine 8), TIL (trypsin-inhibitor-like), E, and D4N modules. The C domains have also been divided into six C regions based on structural studies and by homology with the known structure of other proteins. Platelet binding via the integrin alphaIIbbeta3 (GPIIbIIIa) is assigned to C4. The CTCK crystal structure has revealed a highly reinforced dimerization interface; this extremely strong binding surface explains how large VWF multimers can assemble and resist the exceptionally high shear forces from blood flow at sites of clot formation [
         <a href="#rid102">
          102,108
         </a>
         ].
        </p>
        <p>
         Each mature VWF monomer contains binding sites for collagen, platelet integrins, factor VIII, and other VWF monomers. Since the larger VWF multimers contain repeated binding sites, they are well suited to act as bridging molecules between platelets and the vascular subendothelium: The repeated binding sites allow multiple interactions with both platelet receptors and subendothelial structures at sites of vessel injury. (See
         <a class="local">
          'Bridging between platelets and vascular subendothelium'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3920422049">
         <span class="h2">
          Synthesis and multimerization
         </span>
         <span class="headingEndMark">
          —
         </span>
         VWF is synthesized in endothelial cells and megakaryocytes (platelet precursor cells) [
         <a href="#rid109">
          109,110
         </a>
         ]. The primary translation product contains a signal peptide of 22 amino acids followed by a propeptide of 741 residues, also known as VWF propeptide [
         <a href="#rid111">
          111,112
         </a>
         ]. This polypeptide undergoes considerable post-translational processing. (See
         <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">
          "Basic genetics concepts: DNA regulation and gene expression", section on 'Translation'
         </a>
         .)
        </p>
        <p>
         Post-translational modifications of VWF include [
         <a href="#rid110">
          110,113
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cleavage of the propeptide
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dimerization via disulfide bonds, and multimerization to very large forms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Targeting of larger multimers to storage granules (Weibel-Palade bodies in endothelial cells, alpha granules in platelets)
        </p>
        <p>
        </p>
        <p>
         Several of these processes occur simultaneously.
        </p>
        <p>
         Dimerization occurs early during processing of the protein by formation of interchain disulfide bonds between the C-termini of the pro-VWF within the endoplasmic reticulum [
         <a href="#rid114">
          114
         </a>
         ]. N-linked carbohydrate residues are also added in the endoplasmic reticulum and play a critical role in the formation of dimers and the exit from the endoplasmic reticulum to the Golgi [
         <a href="#rid113">
          113
         </a>
         ]. Further glycosylation and sulfation of the pro-VWF dimers occurs in the Golgi [
         <a href="#rid115">
          115
         </a>
         ]
        </p>
        <p>
         Dimers are assembled into multimers by disulfide bond formation between D3 regions of the N-termini of the pro-dimers. Multimer formation requires the propeptide, a low pH environment, and calcium ions [
         <a href="#rid116">
          116-118
         </a>
         ]. Cleavage of the propeptide sequence by furin occurs at approximately the same time as multimerization, but the propeptide remains to interact with the mature VWF protein to support multimer formation [
         <a href="#rid119">
          119
         </a>
         ]. Multimer sizes are a spectrum, with various numbers of repeating units ranging from tetramers to multimers of &gt;40 to 80 subunits and a size as large as &gt;20 million daltons (&gt;20,000 kilodaltons [kd]) [
         <a href="#rid120">
          120,121
         </a>
         ]. The multimers form flexible 2 nm thick strands in a tangled coil configuration [
         <a href="#rid122">
          122
         </a>
         ]. High shear stress converts the coiled configuration to a linear structure that is more hemostatically active. (See
         <a class="local">
          'Enhanced activity under high shear stress'
         </a>
         below.)
        </p>
        <p>
         Tubule formation, which allows compaction of VWF, occurs during pro-VWF multimerization, and tubule formation drives formation of Weibel-Palade bodies, where VWF is stored as large tubular multimers [
         <a href="#rid123">
          123,124
         </a>
         ]. (See
         <a class="local">
          'Storage and release'
         </a>
         below.)
        </p>
        <p>
         Synthesis of VWF is regulated in part by hormones. As an example, VWF production in endothelial cells is increased by both estrogen and thyroid hormone [
         <a href="#rid125">
          125,126
         </a>
         ]. Increased estrogen levels during pregnancy cause VWF levels to rise during the second and third trimesters [
         <a href="#rid127">
          127
         </a>
         ]; VWF levels decline to nonpregnant values within hours to days after delivery. (See
         <a class="medical medical_review" href="/z/d/html/139017.html" rel="external">
          "von Willebrand disease (VWD): Gynecologic and obstetric considerations", section on 'Pregnancy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139017.html" rel="external">
          "von Willebrand disease (VWD): Gynecologic and obstetric considerations", section on 'Delivery and postpartum care'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4234102007">
         <span class="h2">
          Storage and release
         </span>
         <span class="headingEndMark">
          —
         </span>
         Large VWF multimers are stored in secretory granules in endothelial cells (Weibel-Palade bodies) and platelets (alpha granules) [
         <a href="#rid128">
          128-130
         </a>
         ].
        </p>
        <p>
         Weibel-Palade bodies share several characteristics with lysosomal-related organelles, cell-specific specialized organelles that include platelet dense granules, and melanosomes [
         <a href="#rid131">
          131
         </a>
         ]. Secretion and release of VWF from endothelial cells is polarized (the release pathway is directed to a particular extracellular compartment). A constitutive pathway releases smaller VWF multimers via the basolateral side to the subendothelial matrix of the endothelial cells, while the basal release and regulated release pathways secrete larger VWF multimers via the apical side into the blood vessel lumen [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
         Mechanisms of VWF storage and release from Weibel-Palade bodies are complex and depend on many proteins and signaling molecules [
         <a href="#rid131">
          131,133
         </a>
         ]. Regulation of storage and release differs for different size multimers [
         <a href="#rid132">
          132,134
         </a>
         ]. SNARE proteins are important in the fusion of secretory vesicles with the plasma membrane.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smaller VWF multimers are constitutively secreted from endothelial cells and megakaryocytes. Abluminal secretion from endothelial cells occurs across the basolateral cell membrane, directed to the subendothelial extracellular matrix that contributes to the binding of platelets to the subendothelium of injured blood vessels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Larger, more functional multimers (including "ultralarge" multimers) are targeted to cytoplasmic storage granules for storage (Weibel-Palade bodies in endothelial cells and alpha granules in platelets) [
         <a href="#rid129">
          129
         </a>
         ]. These storage granules contain a variety of other hemostatic factors (P-selectin, tissue plasminogen activator, CD63, osteoprotegerin, angiopoietin-2, interleukin 8, and others [
         <a href="#rid119">
          119,135-138
         </a>
         ]. Coalescence of the Weibel-Palade bodies to form pods occurs before VWF secretion [
         <a href="#rid139">
          139
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6672.html" rel="external">
          "Megakaryocyte biology and platelet production", section on 'Granules'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secretion of the larger, more functional multimers is an active process that occurs by basal (unstimulated) and stimulated secretion pathways.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Basal (unstimulated) secretion of VWF occurs from the basolateral cell membrane of endothelial cells and delivers VWF into the vessel lumen. This process involving endothelial cell VWF is largely responsible for circulating VWF [
         <a href="#rid130">
          130,132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stimulated secretion occurs in response to physiologic agonists, resulting in release of VWF into the vessel lumen, via the apical surface of endothelial cells. Luminal secretion of ultralarge and large multimers enhances VWF binding to platelets (via GPIb) and may also increase the local concentration of factor VIII to enhance clot formation at the site of injury [
         <a href="#rid113">
          113
         </a>
         ]. Agonists include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Alpha-adrenergic agonists such as epinephrine
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Thrombin
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fibrin
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Histamine
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The vasopressin analog DDAVP (used in treatment of VWD) (see
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         During activated release of VWF from Weibel-Palade bodies, the pH rises from the more acidic tubule environment to neutral, and this may allow the tubules to unfold in an orderly manner without tangles [
         <a href="#rid119">
          119,140
         </a>
         ]. The pH change may also allow the cleavage of the prosequence by furin, which occurs at approximately the same time [
         <a href="#rid141">
          141
         </a>
         ].
        </p>
        <p>
         Release of VWF from endothelial cells under shear stress produces long strands of VWF that remain anchored to the endothelial cells by P-selectin [
         <a href="#rid142">
          142
         </a>
         ]. These long strands are assembled under shear using a number of sites in the VWF protein, including unfolded A2 regions that are exposed by shear forces  (
         <a class="graphic graphic_figure graphicRef60152" href="/z/d/graphic/60152.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid143">
          143
         </a>
         ]. This allows binding of additional VWF molecules, platelets, and ADAMTS13, the primary enzyme that breaks down VWF multimers in the circulation [
         <a href="#rid142">
          142,144,145
         </a>
         ]. Ristocetin can mimic the changes induced by shear stress-induced self-association [
         <a href="#rid146">
          146
         </a>
         ]. (See
         <a class="local">
          'Enhanced activity under high shear stress'
         </a>
         below and
         <a class="local">
          'Multimer cleavage by ADAMTS13'
         </a>
         below.)
        </p>
        <p>
         Shear stress-induced self-association of VWF is influenced by several molecules including high-density lipoprotein (HDL) and low-density lipoprotein (LDL):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HDL opposes self-association, decreasing VWF strand size and reducing platelet adhesion [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LDL enhances self-association, increasing the length and thickness of VWF fibers produced under shear [
         <a href="#rid148">
          148
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombospondin-1 decreases self-association by acting as a disulfide reductase [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ADAMTS13 proteolytically cleaves VWF. (See
         <a class="local">
          'Multimer cleavage by ADAMTS13'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3728632712">
         <span class="h2">
          Clearance and control of plasma VWF levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         Circulating VWF concentrations have a wide reference range. The concentration of circulating (plasma) VWF protein is 500 to 1000 mcg/dL, defined as 50 to 150 percent activity. VWF levels are higher than baseline for approximately six months after birth, making it impossible to exclude VWD in newborns. Platelets contain approximately 15 percent of the quantity of VWF present in plasma [
         <a href="#rid150">
          150
         </a>
         ]. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115286.html" rel="external">
          "Laboratory test reference ranges in adults", section on 'von Willebrand factor antigen, plasma'
         </a>
         .)
        </p>
        <p>
         The typical half-life of circulating VWF is approximately 8 to 12 hours; this is determined by the balance between the rates of production (see
         <a class="local">
          'Synthesis and multimerization'
         </a>
         above) and rates of clearance from the circulation.
        </p>
        <p>
         The rate of clearance is in part determined by glycosylation of the VWF protein, which is regulated by fucosyltransferases, ABO blood group glycosyltransferases, and beta-galactoside alpha 2,3 sialyltransferase 4.
        </p>
        <p>
         Adults with blood type O have approximately 25 to 30 percent lower VWF levels than individuals with types A, B, or AB. This is due to a portion of the carbohydrate present on VWF that is similar to the blood groups and influences the clearance of VWF [
         <a href="#rid20">
          20,42,151-157
         </a>
         ]. These physiologic differences may not be present during the first year of life, perhaps related to the slow postnatal development of the blood group system [
         <a href="#rid158">
          158
         </a>
         ].
        </p>
        <p>
         Several different receptors participate in the clearance of VWF from the circulation [
         <a href="#rid159">
          159
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One mechanism involves the loss of terminal sialic acid with aging of the protein (or due to variants in the
         <em>
          VWF
         </em>
         gene), exposing a penultimate galactose residue [
         <a href="#rid160">
          160
         </a>
         ]. Receptors for this mechanism include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The Ashwell-Morrell receptor (which clears hyposialylated N-linked galactose residues) [
         <a href="#rid161">
          161,162
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The macrophage galactose-type lectin receptor (which clears O-linked and N-linked galactose residues) [
         <a href="#rid159">
          159,162
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The LRP1 receptor on macrophages clears VWF via exposure of shear stress-induced interactive sites in VWF [
         <a href="#rid159">
          159
         </a>
         ]. N-linked sites within the VWF A2 domain that are exposed by the unfolding of VWF are able to bind to the LRP1 receptor, which mediates clearance [
         <a href="#rid161">
          161
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CLEC4M receptors, members of the C-type lectin domain family 4, which interact with N-linked glycans, bind to and internalize VWF, decreasing VWF levels [
         <a href="#rid163">
          163
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other genes modifying clearance of VWF include
         <em>
          STAB2
         </em>
         (encodes a lectin-like scavenger receptor that is associated with the clearance of VWF and factor VIII),
         <em>
          STXBP5
         </em>
         ,
         <em>
          SCARA5
         </em>
         ,
         <em>
         </em>
         and
         <em>
          UFM1
         </em>
         [
         <a href="#rid96">
          96,163-167
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2913341892">
         <span class="h2">
          Causes of reduced VWF in acquired VWS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acquired von Willebrand syndrome (AVWS) can be caused by several different mechanisms that affect VWF production, multimerization, or clearance. (See
         <a class="local">
          'Synthesis and multimerization'
         </a>
         above and
         <a class="local">
          'Clearance and control of plasma VWF levels'
         </a>
         above.)
        </p>
        <p>
         Underlying disorders are summarized in the table  (
         <a class="graphic graphic_table graphicRef54202" href="/z/d/graphic/54202.html" rel="external">
          table 2
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/110531.html" rel="external">
          "Acquired von Willebrand syndrome", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2741509516">
         <span class="h1">
          VWF FUNCTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         VWF performs three critical functions in hemostasis [
         <a href="#rid168">
          168,169
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two functions are in primary hemostasis. At sites of injury, VWF acts as a bridging molecule between platelets and vascular subendothelium (platelet adhesion); at high shear stress, VWF promotes platelet aggregation. (See
         <a class="local">
          'Bridging between platelets and vascular subendothelium'
         </a>
         below and
         <a class="local">
          'Enhanced activity under high shear stress'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The third function is in fibrin formation. VWF acts as a carrier for factor VIII in the circulation, increasing the factor VIII half-life fivefold and maintaining normal factor VIII levels, which is essential in the clotting cascade that leads to production of a fibrin clot. (See
         <a class="local">
          'Stabilization of factor VIII'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1423221877">
         <span class="h2">
          Bridging between platelets and vascular subendothelium
         </span>
         <span class="headingEndMark">
          —
         </span>
         VWF functions in primary hemostasis by forming an adhesive bridge between platelets and vascular subendothelial structures as well as between adjacent platelets at sites of vascular injury [
         <a href="#rid113">
          113,170
         </a>
         ]. The binding of VWF to platelets and subendothelial components is critical for normal platelet adhesion.
        </p>
        <p>
         High molecular weight VWF multimers are the most active forms of VWF, providing multiple binding sites that can interact with platelets and subendothelial structures [
         <a href="#rid113">
          113,130,170
         </a>
         ]. (See
         <a class="local">
          'Synthesis and multimerization'
         </a>
         above.)
        </p>
        <p>
         The components in the subendothelial connective tissue to which VWF binds are not completely defined. VWF binds to multiple types of collagen (types I, II, III, IV, V, and VI) [
         <a href="#rid171">
          171,172
         </a>
         ]. Type VI collagen, which binds within the A1 domain, appears to be especially important, both in initial platelet binding and in areas of high shear stress [
         <a href="#rid173">
          173-175
         </a>
         ]. (See
         <a class="local">
          'Enhanced activity under high shear stress'
         </a>
         below.)
        </p>
        <p>
         Binding of collagen types I and III may also be important [
         <a href="#rid176">
          176
         </a>
         ]. Free thiols in the C domain of VWF are a requirement for VWF binding to collagen [
         <a href="#rid177">
          177
         </a>
         ]. Collagen binding appears to induce a conformational change within the factor VIII-binding motif of VWF that lowers the affinity of VWF for factor VIII, perhaps releasing factor VIII locally to aid in the formation of the fibrin clot [
         <a href="#rid178">
          178
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2791689946">
         <span class="h2">
          Enhanced activity under high shear stress
         </span>
         <span class="headingEndMark">
          —
         </span>
         The shear stress that occurs in small arterioles and atherosclerotic arteries (shear rates &gt;1000/second) causes a conformational change in VWF from a globular form to a linear structure in which the A1 domains  (
         <a class="graphic graphic_figure graphicRef60152" href="/z/d/graphic/60152.html" rel="external">
          figure 1
         </a>
         ) are exposed and unhindered by self-association [
         <a href="#rid143">
          143,179
         </a>
         ].
        </p>
        <p>
         The mechanism involves an autoinhibitory module composed of discontinuous sequences located at each end of the A1 domain in VWF, which masks the rest of A1 and prevents the binding of VWF to platelet GPIb. Release of this autoinhibition and exposure of the A1 domain allows platelet GPIb to bind [
         <a href="#rid180">
          180
         </a>
         ]. Ristocetin appears to activate VWF in a similar manner, by exposing A1 for platelet GPIb binding [
         <a href="#rid180">
          180
         </a>
         ].
        </p>
        <p>
         The linear conformation appears to be the functional form for binding to the platelet receptor glycoprotein Ib (GPIb), which engages the GPIb-IX-V complex on the platelet surface and mediates platelet adhesion and aggregation under high shear [
         <a href="#rid60">
          60,66,106,181-185
         </a>
         ]. This interaction is counteracted by circulating beta2 GPI, which binds VWF and inhibits the binding of activated VWF to GPIb, decreasing platelet adhesion. In some autoimmune settings, antibodies to beta2 GPI remove this inhibition of VWF binding, which may contribute to thrombosis [
         <a href="#rid186">
          186,187
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">
          "Clinical manifestations of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p>
         A second platelet receptor for VWF, integrin alphaIIb-beta3 (GPIIbIIIa), does not bind VWF unless the platelets are activated [
         <a href="#rid183">
          183,185
         </a>
         ]. With platelet activation, alphaIIb-beta3 undergoes a conformational change and becomes accessible on the platelet surface. Platelets can be activated by GPIb binding to immobilized VWF strands, which transmits a signal within the platelet [
         <a href="#rid188">
          188
         </a>
         ].
        </p>
        <p>
         The platelet alphaIIb-beta3 interaction with VWF appears to contribute to the final, irreversible binding of platelets to the subendothelium after VWF has bound to GPIb [
         <a href="#rid184">
          184
         </a>
         ]. The alphaIIb-beta3 interaction with VWF may also contribute to platelet aggregation, especially under high shear conditions (under low shear conditions, platelet aggregation is mediated primarily by fibrinogen binding to alphaIIb-beta3) [
         <a href="#rid185">
          185,189-191
         </a>
         ].
        </p>
        <p>
         Vimentin, a structural protein found in plasma and on the surface of platelets, has also been shown to enhance the binding of VWF to the platelet surface under high shear stress [
         <a href="#rid192">
          192
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2933078480">
         <span class="h2">
          Stabilization of factor VIII
         </span>
         <span class="headingEndMark">
          —
         </span>
         Factor VIII is an important protein cofactor in the pathway of thrombin generation. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis"
         </a>
         .)
        </p>
        <p>
         VWF normally binds to and protects factor VIII from proteolytic inactivation by activated protein C and its cofactor protein S [
         <a href="#rid104">
          104,193,194
         </a>
         ]. VWF slows the inactivation of factor VIII by activated protein C by 10-fold to 20-fold [
         <a href="#rid193">
          193,194
         </a>
         ]. In the absence of VWF, the half-life of factor VIII is only approximately two hours [
         <a href="#rid168">
          168,193,194
         </a>
         ]. Since the concentration of VWF is much higher than factor VIII in normal plasma, considerably less than one-half of the normal VWF is required for factor VIII stabilization.
        </p>
        <p>
         VWF domains D' to D3 have been shown to be sufficient to stabilize endogenous factor VIII  (
         <a class="graphic graphic_figure graphicRef120087" href="/z/d/graphic/120087.html" rel="external">
          figure 2
         </a>
         ); this has led to interest in their development as an innovative treatment for hemophilia A [
         <a href="#rid195">
          195
         </a>
         ]. The same product should also be sufficient for treatment of VWD type 2N, although this has not been tested. (See
         <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">
          "Hemophilia A and B: Routine management including prophylaxis", section on 'Efanesoctocog alfa (factor VIII-VWF fusion)'
         </a>
         .)
        </p>
        <p>
         VWF can bind factor VIII only in the inactive form (when factor VIII has not been cleaved by thrombin) [
         <a href="#rid196">
          196
         </a>
         ]. After activation to factor VIIIa by thrombin cleavage, the VWF dissociates  (
         <a class="graphic graphic_figure graphicRef120087" href="/z/d/graphic/120087.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid193">
          193
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2692404146">
         <span class="h2">
          Multimer cleavage by ADAMTS13
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ultralarge VWF multimers can be prothrombotic by promoting platelet-platelet and platelet-endothelial interactions [
         <a href="#rid197">
          197
         </a>
         ]. In vitro evidence indicates that the inflammatory cytokine interleukin (IL)-8 may stimulate the release of ultralarge VWF and IL-6 may inhibit cleavage of the ultralarge multimers, suggesting a connection between inflammation and thrombosis [
         <a href="#rid198">
          198
         </a>
         ]. (See
         <a class="local">
          'Thrombosis associated with high VWF levels'
         </a>
         below.)
        </p>
        <p>
         ADAMTS13 is a member of the "a disintegrin and metalloproteinase with thrombospondin type 1 motif" (ADAMTS) family of metalloproteinases. It is synthesized in hepatic stellate cells, megakaryocytes, platelets, and endothelial cells [
         <a href="#rid199">
          199-202
         </a>
         ]. These cells release ADAMTS13 into the circulation where it can bind large VWF multimers that are unfolded by shear stress, particularly when VWF is bound to platelets.
        </p>
        <p>
         ADAMTS13 cleaves ultralarge VWF multimers at the endothelial cell and platelet surface, converting them to the normal multimer size distribution. It also cleaves smaller (normal size) VWF multimers, leading to a spectrum of multimer sizes. ADAMTS13 contains an active site that cleaves VWF in the A2 domain  (
         <a class="graphic graphic_figure graphicRef60152" href="/z/d/graphic/60152.html" rel="external">
          figure 1
         </a>
         ); the fluid shear stress acting on VWF tethered to the endothelium opens the protein configuration and exposes the bond between amino acids tyrosine 1605 and methionine 1606 (Y1605-M1606) for cleavage [
         <a href="#rid107">
          107,145,203-209
         </a>
         ]. This in turn decrease platelet adhesion and renders the VWF fragments subject to clearance [
         <a href="#rid210">
          210
         </a>
         ].
        </p>
        <p>
         Factor VIII plays a role in accelerating the proteolysis of these ultralarge multimers by ADAMTS13, and factor H, also released by endothelial cells, inhibits cleavage [
         <a href="#rid211">
          211-213
         </a>
         ].
        </p>
        <p>
         Severe deficiency of ADAMTS13 causes microvascular thrombosis in thrombotic thrombocytopenic purpura (TTP). In animal models of ADAMTS13 inhibition, co-inhibition of the VWF-platelet GPIb interaction was shown to abrogate thrombus formation [
         <a href="#rid214">
          214,215
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1331.html" rel="external">
          "Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'Deficient ADAMTS13 activity'
         </a>
         .)
        </p>
        <p>
         Another possible mechanism for processing of the unusually large multimers involves thrombospondin-1, which acts as a protein disulfide reductase and has been shown to reversibly generate new thiol groups in VWF and reduce the size of the multimers [
         <a href="#rid216">
          216
         </a>
         ]. The relative importance of thrombospondin-1 in the determination of the size of plasma VWF multimers is not fully understood. Thrombospondin-1 competes with ADAMTS13 for interaction with the A3 domain of VWF, slowing the proteolysis of VWF by ADAMTS13 [
         <a href="#rid217">
          217
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4000357228">
         <span class="h1">
          MECHANISM OF CLINICAL FINDINGS
         </span>
        </p>
        <p class="headingAnchor" id="H1783070997">
         <span class="h2">
          Bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bleeding can be multifactorial, due to disruption of VWF functions, leading to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased association of platelets with sites of vascular injury
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased aggregation of platelets in regions of high shear stress from rapid blood flow
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced factor VIII activity
        </p>
        <p>
        </p>
        <p>
         In most individuals with type 1 VWD, mucocutaneous bleeding predominates, due primarily to decreased platelet adhesion and aggregation  (
         <a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Type 1 (reduced VWF)'
         </a>
         above.)
        </p>
        <p>
         Severely reduced factor VIII activity and the associated joint and soft tissue bleeding generally only occurs in the less common type 2N disease. (See
         <a class="local">
          'Type 2 (dysfunctional protein; 2A, 2B, 2M, 2N)'
         </a>
         above.)
        </p>
        <p>
         In type 3 disease, absence of VWF eliminates all of these functions and causes both types of bleeding. (See
         <a class="local">
          'Type 3 (undetectable VWF)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4102662357">
         <span class="h2">
          Gastrointestinal angiodysplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angiodysplasia of the gastrointestinal tract has been reported in individuals with hereditary VWD or acquired von Willebrand syndrome (AVWS). However, it is not clear whether this represents a causal association or an increased likelihood of identifying these lesions due to the underlying bleeding disorder. The combination of aortic stenosis and gastrointestinal angiodysplasia has been referred to as Heyde syndrome; this may also represent increased identification due to AVWS related to aortic valve disease. (See
         <a class="medical medical_review" href="/z/d/html/2557.html" rel="external">
          "Angiodysplasia of the gastrointestinal tract", section on 'Conditions associated with angiodysplasia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8164.html" rel="external">
          "Clinical manifestations and diagnosis of aortic stenosis in adults", section on 'Bleeding tendency'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3723773922">
         <span class="h2">
          Thrombosis associated with high VWF levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ultralarge VWF multimers released from platelets and endothelial cells are even more hemostatically active than the largest forms of VWF in normal plasma, and they are considered prothrombotic, binding spontaneously to platelets in the circulation [
         <a href="#rid218">
          218
         </a>
         ].
        </p>
        <p>
         The most striking example is in thrombotic thrombocytopenic purpura (TTP), in which deficiency of ADAMTS13 activity secondary to autoantibodies allows ultralarge VWF multimers to accumulate in small vessels and cause platelet microthrombi to form. (See
         <a class="local">
          'Multimer cleavage by ADAMTS13'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1331.html" rel="external">
          "Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'Consequences of ADAMTS13 deficiency'
         </a>
         .)
        </p>
        <p>
         Elevated VWF levels are also seen in individuals with deep vein thrombosis (DVT) [
         <a href="#rid219">
          219,220
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis", section on 'Other plasma components'
         </a>
         .)
        </p>
        <p>
         Increased VWF levels have been documented in individuals with severe coronavirus disease 2019 (COVID-19), which is a highly prothrombotic state. (See
         <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">
          "COVID-19: Hypercoagulability", section on 'Coagulation abnormalities'
         </a>
         .)
        </p>
        <p>
         Studies in chimeric pigs in which plasma and platelet VWF are dissociated suggest that plasma but not platelet VWF is critical for the development of arterial thrombosis [
         <a href="#rid221">
          221
         </a>
         ]. Thrombosis occurred as expected in pigs with normal plasma VWF and no platelet VWF, while no thrombosis occurred in pigs with absent plasma VWF but normal platelet VWF.
        </p>
        <p class="headingAnchor" id="H101620450">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119323.html" rel="external">
          "Society guideline links: von Willebrand disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15887.html" rel="external">
          "Patient education: von Willebrand disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/697.html" rel="external">
          "Patient education: von Willebrand disease (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H428169728">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/141288.html" rel="external">
          "Patient perspective: von Willebrand disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H718018273">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VWF gene
         </strong>
         – Inherited von Willebrand disease (VWD) was first described in the 1920s; the
         <em>
          VWF
         </em>
         gene was only identified in the 1980s. (See
         <a class="local">
          'Initial description'
         </a>
         above and
         <a class="local">
          'VWF gene'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         VWD is classified into three types  (
         <a class="graphic graphic_table graphicRef71525" href="/z/d/graphic/71525.html" rel="external">
          table 1
         </a>
         ).
         <em>
          VWF
         </em>
         variants are collected in the Leiden Open Variation Database (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdatabases.lovd.nl%2Fshared%2Fvariants%2FVWF%2Funique&amp;token=hwlBMygTvebQR3qzrrjEJ7Gw18NruPiosuiiYFCT0SYU8z11wNpLkR0B%2FD6gBBtITcr9X3Bl6pRFEteRI8xGpw%3D%3D&amp;TOPIC_ID=1309" target="_blank">
          LOVD
         </a>
         ) or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F%3Fterm%3DVWF%255bgene%255d&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trydXpHrlRjlT88GyxPjFjUkN36gYLl74bpR8Ex5bxlDTq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=1309" target="_blank">
          ClinVar
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type 1
         </strong>
         – Decreased VWF levels (&lt;30 percent; 30 to 50 percent in individuals with a bleeding phenotype). Numerous pathogenic variants distributed across the gene that alter VWF production, trafficking, stability, or clearance (Type 1C). Autosomal dominant inheritance. Most common type. (See
         <a class="local">
          'Type 1 (reduced VWF)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type 2
         </strong>
         – Four subtypes, each with different types of disease variants and different alterations in protein function. Type 2A has reduced large multimers. Type 2B has increased platelet binding and thrombocytopenia. Type 2M has decreased platelet binding. Type 2N lacks factor VIII binding. 2A, 2B, and 2M are autosomal dominant; 2N is autosomal recessive. (See
         <a class="local">
          'Type 2 (dysfunctional protein; 2A, 2B, 2M, 2N)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type 3
         </strong>
         – Absent VWF. Autosomal recessive inheritance. Extremely rare. (See
         <a class="local">
          'Type 3 (undetectable VWF)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VWF regulation
         </strong>
         – VWF is a large multimeric glycoprotein  (
         <a class="graphic graphic_figure graphicRef60152" href="/z/d/graphic/60152.html" rel="external">
          figure 1
         </a>
         ) synthesized in endothelial cells and megakaryocytes. Dimerization occurs via interchain disulfide bonds. Multimers form a spectrum of sizes from tetramers to &gt;40 to 80 subunits. They are stored in Weibel-Palade bodies in endothelial cells and alpha granules in platelets. Small multimers are constitutively released; larger multimers undergo basal and stimulated secretion in response to various agonists. The plasma half-life is 8 to 12 hours, with a wide reference range (50 to 150 percent). Adults with blood type O have levels approximately 25 to 30 percent lower than other ABO types. Certain disease states decrease VWF production or increase clearance, causing acquired von Willebrand syndrome. (See
         <a class="local">
          'VWF protein'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VWF functions
         </strong>
         – At sites of injury, VWF bridges between platelets and vascular subendothelium (platelet adhesion). At high shear stress, VWF elongates and promotes platelet aggregation. VWF also binds to factor VIII and dramatically prolongs its half-life  (
         <a class="graphic graphic_figure graphicRef120087" href="/z/d/graphic/120087.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'VWF functions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Mucocutaneous bleeding in type 1 and most type 2 VWD is due to loss of platelet adhesion and aggregation at sites of vascular injury  (
         <a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">
          table 3
         </a>
         ). In type 2N VWD, factor VIII is not stabilized, and factor VIII deficiency leads to joint and soft tissue bleeding. In type 3 VWD, all VWF functions are absent; both types of bleeding are seen. Gastric angiodysplasia is often reported; it is not clear whether this is more common in VWD or more likely to be identified due to the bleeding phenotype. High VWF levels, especially of high molecular weight multimers, can cause thrombosis. (See
         <a class="local">
          'Mechanism of clinical findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and treatment
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">
          "von Willebrand disease (VWD): Treatment of major bleeding and major surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">
          "von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110531.html" rel="external">
          "Acquired von Willebrand syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4225845006">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Margaret E Rick, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nilsson IM. Von Willebrand's disease--fifty years old. Acta Med Scand 1977; 201:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander B, Goldstein R. Dual hemostatic defect in pseudohemophilia. J Clin Invest 1953; 32:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           NILSSON IM, BLOMBACK M, JORPES E, et al. Von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Med Scand 1957; 159:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadler JE, Shelton-Inloes BB, Sorace JM, et al. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A 1985; 82:6394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch DC, Zimmerman TS, Collins CJ, et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 1985; 41:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij CL, de Vries CJ, Distel B, et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res 1985; 13:4699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patracchini P, Calzolari E, Aiello V, et al. Sublocalization of von Willebrand factor pseudogene to 22q11.22-q11.23 by in situ hybridization in a 46,X,t(X;22)(pter;q11.21) translocation. Hum Genet 1989; 83:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 2015; 125:2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4:2103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazurier C, Ribba AS, Gaucher C, Meyer D. Molecular genetics of von Willebrand disease. Ann Genet 1998; 41:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108:3344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eikenboom J, Federici AB, Dirven RJ, et al. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013; 121:2336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021; 5:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campos M, Sun W, Yu F, et al. Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood 2011; 117:5224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnsen JM, Auer PL, Morrison AC, et al. Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project. Blood 2013; 122:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013; 122:3735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jong A, Eikenboom J. Von Willebrand disease mutation spectrum and associated mutation mechanisms. Thromb Res 2017; 159:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanke E, Johansson AM, Halldén C, Lethagen S. Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotype. J Thromb Haemost 2005; 3:2656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eikenboom J, Hilbert L, Ribba AS, et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost 2009; 7:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Othman M, Chirinian Y, Brown C, et al. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 2010; 116:3645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson JD, Yenson PR, Rand ML, et al. Expanded phenotype-genotype correlations in a pediatric population with type 1 von Willebrand disease. J Thromb Haemost 2011; 9:1752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lillicrap D. Translational medicine advances in von Willebrand disease. J Thromb Haemost 2013; 11 Suppl 1:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veyradier A, Boisseau P, Fressinaud E, et al. A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture. Medicine (Baltimore) 2016; 95:e3038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Federici AB, Bucciarelli P, Castaman G, et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011; 37:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batlle J, Pérez-Rodríguez A, Corrales I, et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. Thromb Haemost 2016; 115:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castaman G, Platè M, Giacomelli SH, et al. Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies. J Thromb Haemost 2010; 8:2736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutherland MS, Cumming AM, Bowman M, et al. A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood 2009; 114:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eikenboom JC, Matsushita T, Reitsma PH, et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996; 88:2433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodó I, Katsumi A, Tuley EA, et al. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood 2001; 98:2973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casaña P, Martínez F, Haya S, et al. Association of the 3467C&gt;T mutation (T1156M) in the von Willebrand's factor gene with dominant type 1 von Willebrand's disease. Ann Hematol 2001; 80:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien LA, James PD, Othman M, et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003; 102:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haberichter SL. von Willebrand factor propeptide: biology and clinical utility. Blood 2015; 126:1753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casonato A, Pontara E, Sartorello F, et al. Identifying type Vicenza von Willebrand disease. J Lab Clin Med 2006; 147:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111:3540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 2003; 1:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111:4979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sztukowska M, Gallinaro L, Cattini MG, et al. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 2008; 143:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Paola J, Federici AB, Mannucci PM, et al. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999; 93:3578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunicki TJ, Federici AB, Salomon DR, et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 2004; 104:2359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berber E. The molecular genetics of von Willebrand disease. Turk J Haematol 2012; 29:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267:4424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gralnick HR, Williams SB, McKeown LP, et al. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease. Proc Natl Acad Sci U S A 1985; 82:5968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batlle J, Lopez Fernandez MF, Campos M, et al. The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors. Blood 1986; 68:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassenpflug WA, Budde U, Obser T, et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 2006; 107:2339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginsburg D, Konkle BA, Gill JC, et al. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA. Proc Natl Acad Sci U S A 1989; 86:3723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inbal A, Seligsohn U, Kornbrot N, et al. Characterization of three mutations causing von Willebrand disease type IIA in five unrelated families. Thromb Haemost 1992; 67:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiura I, Matsushita T, Tanimoto M, et al. Three distinct candidate point mutations of the von Willebrand factor gene in four patients with type IIA von Willebrand disease. Thromb Haemost 1992; 67:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai HM, Sussman II, Ginsburg D, et al. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 1997; 89:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brehm MA, Huck V, Aponte-Santamaría C, et al. von Willebrand disease type 2A phenotypes IIC, IID and IIE: A day in the life of shear-stressed mutant von Willebrand factor. Thromb Haemost 2014; 112:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneppenheim R, Michiels JJ, Obser T, et al. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE. Blood 2010; 115:4894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thromb Haemost 1997; 78:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood 1998; 91:2032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobi PM, Gill JC, Flood VH, et al. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood 2012; 119:4543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaucher C, Diéval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaucher C, Uno H, Yamazaki T, et al. A new candidate mutation (N528S) within the von Willebrand factor propeptide identified in a Japanese patient with phenotype IIC of von Willebrand disease. Eur J Haematol 1998; 61:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneppenheim R, Thomas KB, Krey S, et al. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995; 95:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hommais A, Stépanian A, Fressinaud E, et al. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease. Thromb Haemost 2006; 95:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM. Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1991; 266:18172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooney KA, Ginsburg D. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. Blood 1996; 87:2322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998; 273:10396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 3:1702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grainick HR, Williams SB, McKeown LP, et al. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikhail S, Aldin ES, Streiff M, Zeidan A. An update on type 2B von Willebrand disease. Expert Rev Hematol 2014; 7:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson SC, Sinclair GD, Cloutier S, et al. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 2009; 113:3348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss HJ, Sussman II. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986; 68:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss HJ, Meyer D, Rabinowitz R, et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 1982; 306:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller JL, Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 1982; 60:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillery CA, Mancuso DJ, Evan Sadler J, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Jong A, Eikenboom J. Developments in the diagnostic procedures for von Willebrand disease. J Thromb Haemost 2016; 14:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilbert L, Fressinaud E, Ribba AS, et al. Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor. Thromb Haemost 2002; 87:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stepanian A, Ribba AS, Lavergne JM, et al. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease. Br J Haematol 2003; 120:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishino M, Girma JP, Rothschild C, et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazurier C, Dieval J, Jorieux S, et al. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990; 75:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuley EA, Gaucher C, Jorieux S, et al. Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci U S A 1991; 88:6377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rick ME, Krizek DM. Identification of a His54Gln substitution in von Willebrand factor from a patient with defective binding of factor VIII. Am J Hematol 1996; 51:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroner PA, Foster PA, Fahs SA, Montgomery RR. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood 1996; 87:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilbert L, Jorieux S, Proulle V, et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 2003; 120:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casonato A, Sartorello F, Cattini MG, et al. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood 2003; 101:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneppenheim R, Lenk H, Obser T, et al. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost 2004; 92:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piao YC, Lavergne JM, Girma JP, et al. Study of the factor VIII-binding domain of von Willebrand factor in 55 patients with various types of von Willebrand disease. Thromb Haemost 1993; 69:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneppenheim R, Krey S, Bergmann F, et al. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 1994; 94:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ngo KY, Glotz VT, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci U S A 1988; 85:2753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baronciani L, Cozzi G, Canciani MT, et al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baronciani L, Cozzi G, Canciani MT, et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tjernberg P, Castaman G, Vos HL, et al. Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease. Br J Haematol 2006; 133:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders YV, van der Bom JG, Isaacs A, et al. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. J Thromb Haemost 2015; 13:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang ZP, Falk G, Blombäck M, et al. A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients. Hum Mol Genet 1992; 1:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang ZP, Blombäck M, Nyman D, Anvret M. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands. Proc Natl Acad Sci U S A 1993; 90:7937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mannucci PM, Bloom AL, Larrieu MJ, et al. Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel. Br J Haematol 1984; 57:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25:3171.
          </a>
         </li>
         <li class="breakAll">
          Sadler JE. The molecular biology of human von Willebrand factor. In: Coagulation and Bleeding Disorders: The Role of Factor VIII and Von Willebrand Factor, Zimmerman TS, Ruggeri ZM (Eds), Dekker, New York 1989. p.117.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou YF, Eng ET, Zhu J, et al. Sequence and structure relationships within von Willebrand factor. Blood 2012; 120:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz MA, Yuan H, Lee JR, et al. Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J Biol Chem 1995; 270:10822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koppelman SJ, van Hoeij M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87:2292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster PA, Fulcher CA, Marti T, et al. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262:8443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miura S, Li CQ, Cao Z, et al. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 2000; 275:7539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87:4223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou YF, Springer TA. Highly reinforced structure of a C-terminal dimerization domain in von Willebrand factor. Blood 2014; 123:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollestelle MJ, Thinnes T, Crain K, et al. Tissue distribution of factor VIII gene expression in vivo--a closer look. Thromb Haemost 2001; 86:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mojzisch A, Brehm MA. The Manifold Cellular Functions of von Willebrand Factor. Cells 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery RR, Zimmerman TS. von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest 1978; 61:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fay PJ, Kawai Y, Wagner DD, et al. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science 1986; 232:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM, et al. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987; 69:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carew JA, Browning PJ, Lynch DC. Sulfation of von Willebrand factor. Blood 1990; 76:2530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij CL, Hart M, Pannekoek H. Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J 1987; 6:2885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol 1986; 102:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayadas TN, Wagner DD. In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls. J Biol Chem 1989; 264:13497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf DJ, Nightingale TD, Zenner HL, et al. Formation and function of Weibel-Palade bodies. J Cell Sci 2008; 121:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoyer LW, Shainoff JR. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980; 55:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perret BA, Furlan M, Beck EA. Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers. Biochim Biophys Acta 1979; 578:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler WE, Fretto LJ, Hamilton KK, et al. Substructure of human von Willebrand factor. J Clin Invest 1985; 76:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang RH, Wang Y, Roth R, et al. Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci U S A 2008; 105:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentijn KM, Eikenboom J. Weibel-Palade bodies: a window to von Willebrand disease. J Thromb Haemost 2013; 11:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison RL, McKee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 1984; 63:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumgartner-Parzer SM, Wagner L, Reining G, et al. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997; 154:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahieu B, Jacobs N, Mahieu S, et al. Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Blood Coagul Fibrinolysis 2007; 18:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982; 95:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cramer EM, Meyer D, le Menn R, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood 1985; 66:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGrath RT, McRae E, Smith OP, O'Donnell JS. Platelet von Willebrand factor--structure, function and biological importance. Br J Haematol 2010; 148:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharda AV, Barr AM, Harrison JA, et al. VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2. Blood 2020; 136:2824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopes da Silva M, Cutler DF. von Willebrand factor multimerization and the polarity of secretory pathways in endothelial cells. Blood 2016; 128:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood 2008; 112:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McEver RP, Beckstead JH, Moore KL, et al. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989; 84:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989; 73:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vischer UM, Wagner DD. CD63 is a component of Weibel-Palade bodies of human endothelial cells. Blood 1993; 82:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourik MJ, Valentijn JA, Voorberg J, et al. von Willebrand factor remodeling during exocytosis from vascular endothelial cells. J Thromb Haemost 2013; 11:2009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaux G, Abbitt KB, Collinson LM, et al. The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 2006; 10:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rehemtulla A, Kaufman RJ. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes. Blood 1992; 79:2349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004; 103:2150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang C, Kelkar A, Neelamegham S. von Willebrand factor self-association is regulated by the shear-dependent unfolding of the A2 domain. Blood Adv 2019; 3:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Ceunynck K, Rocha S, Feys HB, et al. Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem 2011; 286:36361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100:4033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papi M, Maulucci G, De Spirito M, et al. Ristocetin-induced self-aggregation of von Willebrand factor. Eur Biophys J 2010; 39:1597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung DW, Chen J, Ling M, et al. High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood 2016; 127:637.
          </a>
         </li>
         <li class="breakAll">
          Nussdorfer FD, Taparia N, Feghhi S, et al. LDL and HDL have opposing effects on VWF self-association [abstract]. Blood 2017; 130(suppl 1). Abstract 3601.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan H, Deng N, Zhang S, et al. The unfolded von Willebrand factor response in bloodstream: the self-association perspective. J Hematol Oncol 2012; 5:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nachman RL, Jaffe EA. Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med 1975; 141:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost 2002; 87:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell JS, McKinnon TA, Crawley JT, et al. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005; 106:1988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46:1836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies JA, Collins PW, Hathaway LS, Bowen DJ. Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group. Blood 2007; 109:2840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castaman G, Tosetto A, Eikenboom JC, Rodeghiero F. Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. J Thromb Haemost 2010; 8:2078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klarmann D, Eggert C, Geisen C, et al. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents. Transfusion 2010; 50:1571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casari C, Lenting PJ, Wohner N, et al. Clearance of von Willebrand factor. J Thromb Haemost 2013; 11 Suppl 1:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang WH, Aziz PV, Heithoff DM, et al. An intrinsic mechanism of secreted protein aging and turnover. Proc Natl Acad Sci U S A 2015; 112:13657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chion A, O'Sullivan JM, Drakeford C, et al. N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. Blood 2016; 128:1959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward SE, O'Sullivan JM, Drakeford C, et al. A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood 2018; 131:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rydz N, Swystun LL, Notley C, et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood 2013; 121:5228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith NL, Chen MH, Dehghan A, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Loon J, Dehghan A, Weihong T, et al. Genome-wide association studies identify genetic loci for low von Willebrand factor levels. Eur J Hum Genet 2016; 24:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schillemans M, Karampini E, Hoogendijk AJ, et al. Interaction networks of Weibel-Palade body regulators syntaxin-3 and syntaxin binding protein 5 in endothelial cells. J Proteomics 2019; 205:103417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost 2018; 16:2375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009; 113:5049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santoro SA. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res 1981; 21:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morton LF, Griffin B, Pepper DS, Barnes MJ. The interaction between collagens and factor VIII/von Willebrand factor: investigation of the structural requirements for interaction. Thromb Res 1983; 32:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu XX, Gordon RE, Glanville RW, et al. Morphological relationships of von Willebrand factor, type VI collagen, and fibrillin in human vascular subendothelium. Am J Pathol 1996; 149:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross JM, McIntire LV, Moake JL, Rand JH. Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions. Blood 1995; 85:1826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flood VH, Schlauderaff AC, Haberichter SL, et al. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood 2015; 125:2297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legendre P, Navarrete AM, Rayes J, et al. Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood 2013; 121:2135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien HER, Zhang XF, Sanz-Hernandez M, et al. Blocking von Willebrand factor free thiols inhibits binding to collagen under high and pathological shear stress. J Thromb Haemost 2021; 19:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bendetowicz AV, Wise RJ, Gilbert GE. Collagen-bound von Willebrand factor has reduced affinity for factor VIII. J Biol Chem 1999; 274:12300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88:2939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng W, Voos KM, Colucci JK, et al. Delimiting the autoinhibitory module of von Willebrand factor. J Thromb Haemost 2018; 16:2097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnefoy A, Yamamoto H, Thys C, et al. Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha. Blood 2003; 101:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vicente V, Houghten RA, Ruggeri ZM. Identification of a site in the alpha chain of platelet glycoprotein Ib that participates in von Willebrand factor binding. J Biol Chem 1990; 265:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fredrickson BJ, Dong JF, McIntire LV, López JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998; 92:3684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267:11300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulstein JJ, Lenting PJ, de Laat B, et al. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Laat B, de Groot PG, Derksen RH, et al. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood 2009; 114:3656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang W, Deng W, Zhou L, et al. Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex. Blood 2015; 125:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujimoto T, Ohara S, Hawiger J. Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets. J Clin Invest 1982; 69:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timmons S, Kloczewiak M, Hawiger J. ADP-dependent common receptor mechanism for binding of von Willebrand factor and fibrinogen to human platelets. Proc Natl Acad Sci U S A 1984; 81:4935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254:5357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Da Q, Behymer M, Correa JI, et al. Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. Blood 2014; 123:2715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fay PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266:2172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med 2020; 383:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263:10451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78:1456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu L, Choi H, Bernardo A, et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 3:2536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner N, Nolasco L, Tao Z, et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 4:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108:2207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87:4235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowen DJ, Collins PW. Insights into von Willebrand factor proteolysis: clinical implications. Br J Haematol 2006; 133:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JJ, Fujikawa K, McMullen BA, Chung DW. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci U S A 2006; 103:18470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pruss CM, Notley CR, Hegadorn CA, et al. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor. Br J Haematol 2008; 143:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shim K, Anderson PJ, Tuley EA, et al. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008; 111:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crawley JT, de Groot R, Xiang Y, et al. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118:3212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood 2017; 130:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao W, Krishnaswamy S, Camire RM, et al. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A 2008; 105:7416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao W, Sabatino DE, Altynova E, et al. Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease. J Biol Chem 2012; 287:32459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rayes J, Roumenina LT, Dimitrov JD, et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2014; 123:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feys HB, Roodt J, Vandeputte N, et al. Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood 2012; 120:3611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012; 120:3603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 2001; 193:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pimanda JE, Ganderton T, Maekawa A, et al. Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem 2004; 279:21439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998; 57:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagliari MT, Boscarino M, Cairo A, et al. ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. Thromb Res 2021; 197:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rietveld IM, Lijfering WM, le Cessie S, et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost 2019; 17:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols TC, Samama CM, Bellinger DA, et al. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A 1995; 92:2455.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1309 Version 42.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/327757" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Von Willebrand's disease--fifty years old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Dual hemostatic defect in pseudohemophilia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13508084" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Von Willebrand's disease and its correction with human plasma fraction 1-0.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6438525" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Characterization of the human factor VIII gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6438528" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Molecular cloning of a cDNA encoding human antihaemophilic factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3874428" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2864688" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cloning and characterization of two cDNAs coding for human von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3873280" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3875078" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2793170" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Sublocalization of von Willebrand factor pseudogene to 22q11.22-q11.23 by in situ hybridization in a 46,X,t(X;22)(pter;q11.21) translocation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25712991" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16889557" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9759493" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Biochemistry and genetics of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9599650" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Molecular genetics of von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16835381" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23349392" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33570651" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21343614" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23690449" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3495304" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The effect of ABO blood group on the diagnosis of von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20409624" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The genetic basis of von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24065240" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28987708" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Von Willebrand disease mutation spectrum and associated mutation mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16985174" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17190853" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16359504" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19566550" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696945" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21711445" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Expanded phenotype-genotype correlations in a pediatric population with type 1 von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23809112" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Translational medicine advances in von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26986123" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22102194" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26245874" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20854374" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19372260" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8839833" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11698279" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11529461" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association of the 3467C&gt;T mutation (T1156M) in the von Willebrand's factor gene with dominant type 1 von Willebrand's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12649144" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26215113" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : von Willebrand factor propeptide: biology and clinical utility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16459168" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Identifying type Vicenza von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18245665" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12911582" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344424" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18691167" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10339461" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15226188" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24385719" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The molecular genetics of von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1537829" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2994057" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3490883" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16322474" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2786201" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1324533" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Characterization of three mutations causing von Willebrand disease type IIA in five unrelated families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1380739" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Three distinct candidate point mutations of the von Willebrand factor gene in four patients with type IIA von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9058716" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24598842" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : von Willebrand disease type 2A phenotypes IIC, IID and IIE: A day in the life of shear-stressed mutant von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20351307" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9198195" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9490688" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431572" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8049421" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9714529" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A new candidate mutation (N528S) within the von Willebrand factor propeptide identified in a Japanese patient with phenotype IIC of von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7789955" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Identification of a candidate missense mutation in a family with von Willebrand disease type IIC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16676067" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1917949" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor binding to platelet glycoprotein Ib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8630394" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9553097" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16102036" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : von Willebrand factor: two sides of a coin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2932469" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6767976" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24521271" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : An update on type 2B von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18805962" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19060241" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3487353" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6798442" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6286015" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Platelet-type von Willebrand's disease: characterization of a new bleeding disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9473222" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26714181" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Developments in the diagnostic procedures for von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12008946" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12588351" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2506947" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : New variant of von Willebrand disease with defective binding to factor VIII.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2104761" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1906179" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8602631" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Identification of a His54Gln substitution in von Willebrand factor from a patient with defective binding of factor VIII.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8562925" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12588349" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393698" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15213842" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Study of the factor VIII-binding domain of von Willebrand factor in 55 patients with various types of von Willebrand disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7989040" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Genetic heterogeneity of severe von Willebrand disease type III in the German population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3258663" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11057846" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12737944" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16643449" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25832887" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1302613" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8367445" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6609712" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3524673" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Amino acid sequence of human von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3524673" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Amino acid sequence of human von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22490677" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Sequence and structure relationships within von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7738019" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8630390" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3110147" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10713059" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639781" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24394662" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Highly reinforced structure of a C-terminal dimerization domain in von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11583319" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Tissue distribution of factor VIII gene expression in vivo--a closer look.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34572000" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : The Manifold Cellular Functions of von Willebrand Factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/307007" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3486471" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2275814" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Cell biology of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3539228" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Topology and order of formation of interchain disulfide bonds in von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2265247" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Sulfation of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3500851" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3082891" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2788160" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18096688" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Formation and function of Weibel-Palade bodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6769518" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/454664" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2932468" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Substructure of human von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18182488" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23398618" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Weibel-Palade bodies: a window to von Willebrand disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6607757" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Estrogen stimulates von Willebrand factor production by cultured endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9291833" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17890957" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6754744" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3875375" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20067560" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Platelet von Willebrand factor--structure, function and biological importance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32614949" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27106123" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : von Willebrand factor multimerization and the polarity of secretory pathways in endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12871401" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344423" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Basal secretion of von Willebrand factor from human endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2472431" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2467701" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8353283" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : CD63 is a component of Weibel-Palade bodies of human endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14976056" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24010820" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : von Willebrand factor remodeling during exocytosis from vascular endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16459301" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1571548" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630802" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30936056" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : von Willebrand factor self-association is regulated by the shear-dependent unfolding of the A2 domain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21896483" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393397" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20589372" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Ristocetin-induced self-aggregation of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26552698" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26552698" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23067373" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : The unfolded von Willebrand factor response in bloodstream: the self-association perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1168691" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Subcellular platelet factor VIII antigen and von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12083507" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11834538" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12871537" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15886321" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17002642" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17119126" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20561182" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20210927" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23809124" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Clearance of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26489654" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : An intrinsic mechanism of secreted protein aging and turnover.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27554083" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29282218" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23529928" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231535" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26486471" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Genome-wide association studies identify genetic loci for low von Willebrand factor levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31201948" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Interaction networks of Weibel-Palade body regulators syntaxin-3 and syntaxin binding protein 5 in endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30246494" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Genetic regulation of plasma von Willebrand factor levels in health and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3936044" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318682" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : von Willebrand factor to the rescue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8440408" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6791300" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6420928" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : The interaction between collagens and factor VIII/von Willebrand factor: investigation of the structural requirements for interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8686752" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Morphological relationships of von Willebrand factor, type VI collagen, and fibrillin in human vascular subendothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7703489" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25662333" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Crucial role for the VWF A1 domain in binding to type IV collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23335371" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33075181" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Blocking von Willebrand factor free thiols inhibits binding to collagen under high and pathological shear stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10212199" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Collagen-bound von Willebrand factor has reduced affinity for factor VIII.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8874190" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30053340" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Delimiting the autoinhibitory module of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393553" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2104618" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Identification of a site in the alpha chain of platelet glycoprotein Ib that participates in von Willebrand factor binding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565074" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9808562" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1597464" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488878" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19706887" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25359992" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6282932" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6087354" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : ADP-dependent common receptor mechanism for binding of von Willebrand factor and fibrinogen to human platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/447655" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Human platelets possess an inducible and saturable receptor specific for fibrinogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24642750" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2971673" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1846615" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32905674" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3134349" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Association of the factor VIII light chain with von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3491092" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15026315" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806136" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : ADAMTS13 is expressed in hepatic stellate cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16176307" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Platelet-derived VWF-cleaving metalloprotease ADAMTS-13.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16706987" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Human endothelial cells synthesize and release ADAMTS-13.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16597588" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639782" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393734" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16681634" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Insights into von Willebrand factor proteolysis: clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17121983" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18986390" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17901248" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715306" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28768626" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : Pathophysiology of thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18492805" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22854959" id="rid211" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          212 : Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24014239" id="rid212" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          213 : The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22855603" id="rid213" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          214 : Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22948047" id="rid214" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          215 : Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11413189" id="rid215" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          216 : Control of von Willebrand factor multimer size by thrombospondin-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14981081" id="rid216" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          217 : Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9544973" id="rid217" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          218 : Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33212380" id="rid218" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          219 : ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30471183" id="rid219" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          220 : High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7708664" id="rid220" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          221 : Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
